You have found 141 entries after clicking the GO button or a search link in a hot topic. Starting with the most recently added or updated entries, the list shows in orange the type of entry, year the original document was published (or if one of our own documents, the year last updated), and the type of file you will download when you click on the title. In blue is the document’s title followed by a brief description.
Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Re-order the list by the main topic addressed or by the most recently published documents
If you have not found what you want you could:
Select from the full range of topics and search options available on our topic search page.
Instead try a free text search for documents which contain the words you specify.
Or try browsing back issues of the magazine or recent bulletins.
Documents are regularly added. Use the e-mail update service to monitor additions.
Try the information services provided by partner agencies.
Tried everything? E-mail the Findings editor for help by clicking on this logo
REVIEW 2013 HTM file
Maintenance agonist treatments for opiate dependent pregnant women
Is it better to prescribe pregnant opioid-dependent women methadone, buprenorphine or oral morphine? Just four randomised trials have addressed this issue and their findings are inconclusive, suggesting greater holding power for methadone but less severe neonatal withdrawal with buprenorphine.
Can a limited period of being prescribed opiate-type medications generate longer term reductions in the criminal behaviour of patients dependent on illegal opiates like heroin? And of the two main medications – buprenorphine and methadone – which performs best? It seems a key factor is how well they retain patients in treatment.
How do different pathways for the treatment of problem opioid use compare under real-world conditions? For US patients with health insurance, opioid substitution therapy was associated with the greatest risk reduction. However, its protective effect may not be fully realised while federal and insurance plan restrictions continue to limit access to this treatment option.
In the Canadian province of British Columbia there was a rapid rise in overdose deaths from 2015, leading to the declaration of a public health emergency in 2016. The response rested on three key interventions: take-home naloxone, opioid substitution therapy, and drug consumption rooms. The province’s highly detailed surveillance data offered an opportunity to estimate their collective and individual impacts on opioid overdose deaths.
STUDY 2012 HTM file
Housing first for severely mentally ill homeless methadone patients
Homelessness is a significant obstacle to regular participation in methadone maintenance treatment, particularly among people leaving prison. This study in a major US city examines whether a ‘housing first’ programme could improve outcomes among this cohort.
The UK has a long history of prescribing heroin for the treatment of heroin dependence. What has research from six countries concluded about this intensive intervention intended for patients who would otherwise be considered ‘unresponsive’ to treatment?
In the new form of extended-release injections with effects lasting a month, the opioid medication buprenorphine was found to suppress illegal opioid use more effectively than a placebo, reinforcing its promise as a possible “game-changer” in opiate addiction treatment.
Opioid substitution therapy is a safe and effective approach for suppressing illicit opioid use. Helping to guide optimal provision, this review investigates the relative effects of methadone and buprenorphine on the rate of mortality over time.
REVIEW 2016 HTM file
Buprenorphine versus methadone for opioid dependence in pregnancy
Among pregnant women, substitute prescribing is preferable to continued illicit opioid use and supervised withdrawal. Buprenorphine has different properties to the dominant treatment option methadone, but both stand to improve pregnancy and infant outcomes.
In the new form of extended-release injections whose effects last up to a month, the opioid medication buprenorphine was found to suppress illegal opioid use more effectively than the standard daily regimen.
Select search results pageNEXT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15